FDA Approved a New Tx for DMD – Agamree
There was a big development for DMA patients last June with the FDA approval of Elevidys (delandistrogene moxeparvovec-rokl) from Sarepta Therapeutics. Elevidys was the first and
February 6, 2024
There was a big development for DMA patients last June with the FDA approval of Elevidys (delandistrogene moxeparvovec-rokl) from Sarepta Therapeutics. Elevidys was the first and
I always enjoy news about innovative developments in pharmacy. The article below tickled our interest. The article details how Texas A&M has successfully developed a
When a Fortune 100 company breaks the mold on anything it is news. Recently, Tyson Foods made a mold-breaking move and showed it was not averse
There has been scant news over the past year about big moves involving sales and strategic acquisitions in the specialty pharmacy space. Today my internet
Earlier this week we sent a Report outlining why the term ‘BioBETTER’ should be added to your pharma vocabulary. Today we introduce a new biosimilar that
What is a Biobetter? An article published by the Center for Biosimilars used a new word to the specialty pharmacy lexicon…… BioBetter….. prompting us to
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
There was a flood of media coverage following the FDA’s announcement that they have approved Florida’s request to import low-cost drugs from Canada. While that may
………. Catching up on FDA approvals The FDA approved a new therapy at the tail end of last year (it was November and, yes, we are
Happy New Year….. or to be said otherwise, What’s Happy About It? The article below doesn’t trumpet the benefit of the changes implemented by Congress
